Genomic Vision (GV.PA) Stock Price
Genomic Vision Price
Revenue at Genomic Vision has contracted by 11.3% per year over the past 11 years to 1.03 M EUR. For Genomic Vision, the net margin of -661.8% is down versus -619.8% a few years ago. The stock trades about 39% above its 52-week low.
Genomic Vision stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Genomic Vision over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Genomic Vision stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Genomic Vision's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Genomic Vision Price |
|---|---|
| 9/3/2026 | 1,222.69 EUR |
| 9/2/2026 | 1,223.72 EUR |
| 9/1/2026 | 1,247.58 EUR |
| 8/31/2026 | 1,242.49 EUR |
| 8/28/2026 | 1,243.47 EUR |
| 8/27/2026 | 1,243.72 EUR |
| 8/26/2026 | 1,235.75 EUR |
| 8/25/2026 | 1,223.12 EUR |
| 8/24/2026 | 1,216.73 EUR |
| 8/21/2026 | 1,240.44 EUR |
| 8/20/2026 | 1,226.41 EUR |
| 8/18/2026 | 1,225.27 EUR |
| 8/17/2026 | 1,237.51 EUR |
| 8/14/2026 | 1,228.41 EUR |
| 8/13/2026 | 1,224.28 EUR |
| 8/12/2026 | 1,212.25 EUR |
| 8/11/2026 | 1,198.63 EUR |
| 8/10/2026 | 1,199.66 EUR |
| 8/7/2026 | 1,185.98 EUR |
| 8/6/2026 | 1,186.58 EUR |
| 8/5/2026 | 1,206.95 EUR |
| 8/4/2026 | 1,176.66 EUR |
| 8/3/2026 | 1,173.90 EUR |
| 7/31/2026 | 1,187.52 EUR |
| 7/30/2026 | 1,102.49 EUR |
| 7/29/2026 | 1,107.38 EUR |
| 7/28/2026 | 1,126.02 EUR |
| 7/27/2026 | 1,179.40 EUR |
| 7/24/2026 | 1,168.75 EUR |
| 7/23/2026 | 1,206.86 EUR |
Genomic Vision Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Genomic Vision Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM EUR |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM EUR |
| EBITM EUR |
| EBIT MARGIN% |
| NET INCOMEM EUR |
| NET INCOME GROWTH% |
| SHARESM |
| 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.00 | 2.00 | 2.00 | 3.00 | 2.00 | 1.00 | 2.00 | 1.00 | 1.00 | 1.00 | – | 1.00 |
| – | -33.33 | – | 50.00 | -33.33 | -50.00 | 100.00 | -50.00 | – | – | – | – |
| 33.33 | -50.00 | 50.00 | 100.00 | 100.00 | -100.00 | -50.00 | -200.00 | -100.00 | -100.00 | – | -100.00 |
| 1.00 | -1.00 | 1.00 | 3.00 | 2.00 | -1.00 | -1.00 | -2.00 | -1.00 | -1.00 | -1.00 | -1.00 |
| – | -1.00 | -1.00 | -2.00 | -4.00 | -8.00 | -8.00 | -6.00 | -4.00 | -5.00 | -4.00 | -6.00 |
| – | -50.00 | -50.00 | -66.67 | -200.00 | -800.00 | -400.00 | -600.00 | -400.00 | -500.00 | – | -600.00 |
| – | -1.00 | -1.00 | -2.00 | -4.00 | -8.00 | -9.00 | -6.00 | -4.00 | -5.00 | -4.00 | -6.00 |
| – | – | – | 100.00 | 100.00 | 100.00 | 12.50 | -33.33 | -33.33 | 25.00 | -20.00 | 50.00 |
| 2.36 | 2.36 | 2.49 | 4.00 | 4.46 | 4.46 | 4.94 | 8.49 | 28.33 | 45.39 | 50.27 | 70.54 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Genomic Vision generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Genomic Vision retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Genomic Vision's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Genomic Vision has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Genomic Vision's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Genomic Vision stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Genomic Vision Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Genomic Vision business model & stock analysis
Genomic Vision SWOT Analysis
Strengths
Genomic Vision SA has several key strengths that contribute to its competitive advantage in the market. These strengths include:
- Advanced and innovative technology in genomic analysis
- Strong intellectual property portfolio
- Experienced and skilled research and development team
- Strong partnerships with key industry players
- Established brand reputation and customer trust
Weaknesses
Despite its strengths, Genomic Vision SA also faces certain weaknesses that could hinder its growth and success. These weaknesses include:
- Reliance on a limited number of customers for revenue generation
- High costs associated with research and development
- Limited market reach and penetration
- Dependency on external funding for expansion and operations
- Challenges in translating research into commercially viable products
Opportunities
Genomic Vision SA can capitalize on various opportunities in the market to drive growth and profitability. These opportunities include:
- Increasing demand for genomic analysis in various industries
- Emergence of personalized medicine and precision diagnostics
- Expansion into new geographical markets and segments
- Collaborations with renowned research institutions and organizations
- Technological advancements enhancing the efficiency and accuracy of genomic analysis
Threats
Genomic Vision SA should be mindful of potential threats that could impact its operations and growth prospects. These threats include:
- Intense competition from established and emerging players in the genomics industry
- Changing regulations and compliance requirements
- Uncertainty in government funding for research and development
- Potential cybersecurity risks and data breaches
- Negative public perception or ethical concerns regarding genomic analysis
Genomic Vision Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Genomic Vision historical P/E ratio, EBIT multiple, and P/S ratio
Genomic Vision annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Genomic Vision shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Genomic Vision shareholder structure
| % | Name |
|---|---|
0.00000% |
Genomic Vision Beneficial Ownership Filings (SEC 13D/G)
Genomic Vision Executives and Management Board
8 members · 38 % women
Mr. Aaron Bensimon
Chief Executive Officer, Member of the Management Board
331,410.00 EUR
Management
Mr. Jerome Vailland
Chief Financial Officer, Member of the Management Board
Board of Directors
Ms. Elisabeth Ourliac
Independent Chairwoman of the Supervisory Board · since 2017
Ms. Tamar Saraga
Independent Member of the Supervisory Board
Mrs. Dominique Remy-Renou
Chairwoman of the Management Board
Mr. Stephane Verdood
Vice Chairman of the Supervisory Board · since 2008
Mr. Mark Lynch
Director of Global Sales, Director of Marketing
Dr. Thierry Huet
Director of Research and Development
Frequently asked questions about Genomic Vision
The business model of Genomic Vision SA revolves around developing and commercializing innovative molecular diagnostic solutions for genetic diseases and cancer. Their proprietary technology, known as molecular combing, allows for the identification and analysis of genetic abnormalities with high precision and sensitivity. By partnering with pharmaceutical and biotech companies, Genomic Vision SA aims to provide personalized and reliable diagnostics that can guide treatment decisions and enable targeted therapies. This business model positions Genomic Vision SA as a leader in the field of molecular diagnostics, offering valuable insights into the understanding, prevention, and management of genetic disorders and oncology.
Genomic Vision SA is primarily active in the biotechnology and healthcare industries.
The main competitors of Genomic Vision SA in the market include companies such as Illumina, Inc., Thermo Fisher Scientific Inc., Pacific Biosciences of California, Inc., and Bionano Genomics, Inc. These companies operate in the field of genomics and offer technologies and solutions related to genetic analysis and molecular diagnostics. They compete with Genomic Vision SA in terms of developing innovative genomic platforms, products, and services to cater to the needs of various industries, including healthcare, pharmaceuticals, research institutions, and more.
Genomic Vision SA is a leading biotechnology company specializing in molecular diagnostics and analysis of genetic diseases. Founded in 2004 and headquartered in France, Genomic Vision aims to revolutionize genetic testing through its innovative molecular combing technology. This technique enables the direct visualization and study of the genome structure, allowing for the identification of genetic abnormalities and the development of personalized medicine. Genomic Vision has also established strategic partnerships with renowned institutions and industry leaders to further advance its proprietary technology. With its dedication to driving precision medicine, Genomic Vision SA continues to make significant contributions to the field of genomics and enhance the lives of patients worldwide.
Genomic Vision SA has achieved several significant milestones in its history. One notable achievement is the development of the proprietary Molecular Combing technology, which enables the direct visualization and analysis of single DNA molecules. This groundbreaking innovation has positioned Genomic Vision SA as a leader in genetic testing and diagnostics. Additionally, the company has successfully collaborated with renowned research institutions and industry partners to validate its technology and expand its applications in various fields, including cancer research, rare genetic diseases, and agrigenomics. With its continuous efforts in advancing genomic medicine, Genomic Vision SA is making notable contributions to the field of molecular diagnostics.
Genomic Vision SA is primarily present in various countries and regions across the world. With its headquarters in France, the company has a strong presence in Europe, including countries like Germany, the United Kingdom, Spain, Italy, and Switzerland. Additionally, Genomic Vision SA has established significant operations and partnerships in North America, particularly in the United States and Canada. The company also has a growing presence in Asia, with a focus on countries like China, Japan, and South Korea. Genomic Vision SA's global reach showcases its commitment to expanding its innovative genomic analysis solutions worldwide.
Genomic Vision SA is a leading company that focuses on the development of innovative genomic solutions. With a strong commitment to the advancement of genetic research, the company values excellence, collaboration, and integrity. Genomic Vision SA follows a corporate philosophy aimed at improving human health through cutting-edge technology and accurate genetic analyses. By leveraging their expertise in molecular combing and genomic profiling, Genomic Vision SA is dedicated to providing reliable and efficient diagnostic solutions for various genetic diseases. With its emphasis on progress and scientific excellence, Genomic Vision SA strives to contribute to the betterment of healthcare and the understanding of human genetics.
8 analysts currently rate the Genomic Vision stock: 0 recommend buying, 2 holding and 6 selling.
The Genomic Vision share (GV.PA) is listed on 5 stock exchanges, including: Frankfurt (G09.F), München (G09.MU), London (0QT4.L), Paris (GV.PA).
Genomic Vision SA is a French biotechnology company specializing in the development and commercialization of molecular genetic solutions for research, diagnosis, and treatment of genetic diseases. The company was founded in 2004 and has its headquarters in Bagneux, France.
The revenue cannot currently be calculated for Genomic Vision.
The profit cannot currently be calculated for Genomic Vision.
The P/E ratio cannot be calculated for Genomic Vision at the moment.
The P/S cannot be calculated for Genomic Vision currently.
The Eulerpool Quality Score for Genomic Vision is 2/10.
The ISIN of Genomic Vision is FR0011799907. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Genomic Vision is A110TM. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Genomic Vision is GV.PA. The ticker symbol is used to trade Genomic Vision shares on the stock exchange.
Genomic Vision paid dividends every year for the past 0 years.
Genomic Vision is assigned to the 'Health' sector.
The dividends of Genomic Vision are distributed in EUR.
Genomic Vision stock
Genomic Vision Peer Group
Genomic Vision Ticker
Genomic Vision FIGI
All fundamentals and in-depth analysis of Genomic Vision
Our stock analysis for Genomic Vision stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Genomic Vision. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.